Program
INCB057643
Its studies are mostly in Primary Myelofibrosis · Neoplasm Metastasis · Lymphoma, led by Incyte.
Furthest: phase 2, since Mar 9, 20164 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 41 open or running | phase 2since Mar 9, 2016 | Mar 9, 2016 | Apr 30, 2027phase 1 · NCT04279847 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2016First study: phase 2 study in LymphomaFirst studyNCT02711137 · 137 enrolled · United States, Belgium, France
- Nov 7, 2016Phase 2 study in Neoplasm MetastasisNCT02959437 · 70 enrolled · United States, Spain, United Kingdom
- Feb 18, 2020Phase 1 study in Primary MyelofibrosisNCT04279847 · 140 enrolled · United States, Canada, China and more
- Apr 16, 2025Phase 1 study in Healthy VolunteersNCT06941077 · 48 enrolled · United States
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Primary MyelofibrosisNCT04279847
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06941077Healthy Volunteers · United States | 1 | Completed | Jun 3, 2025 | 48 |
| NCT04279847Primary Myelofibrosis · United States, Canada, China and more | 1 | Active, not recruiting | Apr 30, 2027 | 140 |
| NCT02959437Neoplasm Metastasis · United States, Spain, United Kingdom | 2 | Terminated | Feb 15, 2019 | 70 |
| NCT02711137Lymphoma · United States, Belgium, France | 2 | Terminated | Feb 13, 2019 | 137 |
How it is read
Names in the registry
- “INCB057643”, 4 entries
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 1 study
- Neoplasm Metastasis, 1 study
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.